GIGABYTE Launches Z890 Plus Series Motherboards Supporting Intel Core Ultra 200S Plus Series Processors and CQDIMM Technology
TAIPEI, March 11, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand,…
Artmarket.com publishes its 32nd Artprice Annual Report – The Art Market in 2025 – showing 12% growth, with the USA strengthening its dominant position. Plus Gemini Deep Think’s AI audit of Artprice’s strategy for 2026/2030
PARIS, March 10, 2026 /PRNewswire/ -- The 32nd Artprice Annual Report –…
Paingone Plus TENS Pen Featured in 2026 Consumer Report Examining FDA Clearance Status, TENS Pain Therapy Research, and Portable Pain Relief Device Verification
Tukwila, WA, March 05, 2026 (GLOBE NEWSWIRE) -- This report examines publicly…
Landmark Study Demonstrates Sustained Clinical Benefits of Flexitouch Plus as First-Line Therapy in Treating Head and Neck Cancer-Related Lymphedema
October 28, 2025 16:05 ET | Source: Tactile Systems Technology, Inc. MINNEAPOLIS,…
DFSK Celebrates 20 Years of Global Expansion with E5 PLUS, the First Overseas New Energy Strategic Model, Rolls Off the Production Line
CHONGQING, China, Oct. 22, 2025 /PRNewswire/ -- On October 22, 2025, at…
IO Biotech Presents Phase 3 Results for Cylembio plus KEYTRUDA (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
October 20, 2025 02:30 ET | Source: IO Biotech Cylembio plus pembrolizumab…
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
October 19, 2025 08:00 ET | Source: Replimune, Inc. WOBURN, Mass., Oct.…
Sandstone Easydrip Plus Pen Needles Debut in Turkey — PatentProtected Hexagonal Hub for Comfort and Control
Large‑platform hexagonal hub (Hextra Tech) offers superior stability and ease of grip;…
FDA approves Roches Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer
Combination reduced the risk of disease progression or death by 46% and…
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Nave or Resistant R/M-HNSCC
Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients…
